低钠血症 中国就医指南

Hyponatremia is a common and potentially life-threatening electrolyte disorder characterized by a serum sodium concentration below 135 mmol/L. It reflects an imbalance between water and sodium homeostasis—not necessarily a true deficiency of total-body sodium, but rather a relative excess of water or impaired renal water excretion. Pathophysiologically, hyponatremia arises from dysregulation of antidiuretic hormone (ADH), impaired renal solute excretion, or excessive hypotonic fluid intake. Key mechanisms include the syndrome of inappropriate ADH secretion (SIADH), adrenal insufficiency, hypothyroidism, heart failure, cirrhosis, thiazide diuretic use, and postoperative stress. In endocrinology practice, hyponatremia frequently signals underlying hormonal dysfunction—especially glucocorticoid deficiency (e.g., Addison’s disease) or central hypothyroidism—and warrants thorough evaluation of pituitary-adrenal-thyroid axes. Epidemiologically, hyponatremia affects approximately 5–30% of hospitalized patients, with prevalence rising to over 40% in elderly populations and those with chronic illnesses such as heart failure, liver cirrhosis, or advanced malignancy. Community-based studies estimate a prevalence of 1–2% among ambulatory adults, increasing markedly with age and polypharmacy. Major risk factors include female sex (particularly premenopausal women due to estrogen’s effect on ADH sensitivity), advanced age (>65 years), use of SSRIs or thiazides, low body weight, and comorbid endocrine disorders like hypopituitarism or adrenal insufficiency. Acute hyponatremia (<48 hours) can cause rapid cerebral edema, leading to headache, nausea, confusion, seizures, coma, and death. Chronic hyponatremia (>48 hours) often presents subtly with gait instability, attention deficits, fatigue, and mild cognitive impairment—symptoms easily mistaken for normal aging or depression. Importantly, even mild chronic hyponatremia (130–135 mmol/L) is independently associated with increased fracture risk, falls, and all-cause mortality. Quality of life is significantly compromised: patients report reduced physical stamina, diminished concentration, emotional lability, and social withdrawal. Untreated or mismanaged hyponatremia contributes to prolonged hospital stays, higher readmission rates, and functional decline—especially in older adults. Early recognition, accurate classification (hypovolemic, euvolemic, or hypervolemic), and targeted endocrine workup are essential to reverse underlying causes and prevent osmotic demyelination syndrome during correction. Multidisciplinary management involving endocrinologists, nephrologists, and clinical pharmacists improves diagnostic accuracy and therapeutic safety.

# 低钠血症（内分泌科）治疗方案与费用明细

一、非手术/保守治疗方案

适用人群：轻中度（血钠125–135 mmol/L）、无显著神经系统症状、病因可逆者（如药物性、SIADH、心衰、肝硬化）。

• •基础干预：限水（<800–1000 mL/d）、停用噻嗪类利尿剂/SSRIs等诱因药物
• •药物治疗：

- 托伐普坦（国产仿制药）：15 mg/d，450–900元/月；原研药1800–2400元/月

• •检验监测：电解质+渗透压+甲状腺功能+皮质醇+AVP检测（含急诊生化），320–580元/次

二、静脉纠正治疗（内分泌科核心干预）

适用人群：中重度（血钠<125 mmol/L）、有头痛/意识模糊/抽搐者。

• •0.9%氯化钠或3%高渗盐水输注（严格监护下）：药品费80–200元/疗程，含中心静脉置管及每小时电解质监测（120元/次×4–8次）
• •总住院日均费用（三甲内分泌科病房）：1800–3200元/天（含护理、监护、多学科会诊）

三、病因根治性干预（非手术）

适用人群：垂体ACTH缺乏、肾上腺皮质功能减退、恶性肿瘤相关SIADH等。

• •氢化可的松替代治疗（长期）：120–260元/月（国产）
• •肿瘤评估（胸部CT+腹部超声+肿瘤标志物）：1200–2100元/套

四、特殊复杂情况处理

• •顽固性低钠+严重脑水肿：ICU监护下高渗盐水联合连续性肾脏替代治疗（CRRT）：8000–15000元/天
• •慢性低钠合并认知障碍：神经内分泌评估+个体化限水教育随访（门诊年管理费）：2400–4800元/年

方案快速选择指南

✅ 预算有限/轻症：门诊限水+口服补钠+基础检验（总费用≤1200元） ✅ 中重度需住院：内分泌科规范静脉纠正+病因筛查（5–7日住院，总费用1.6–3.5万元） ✅ 疑难复发/肿瘤相关：启动多学科（内分泌+肿瘤+肾内）联合诊疗路径（首期评估费用约4000–6500元）